Gallus BioPharmaceuticals (Gallus), a biologics contract manufacturing organization, has signed a manufacturing agreement with Symphogen, A/S (Symphogen), a private biopharmaceutical company developing recombinant monoclonal antibody (mAb) mixtures for the treatment of cancer.  This agreement includes process transfer and clinical-stage cGMP manufacturing of Symphogen's antibody mixture product candidates. Gallus will employ the GE Healthcare Life Sciences Flex Factoryâ„¢, a flexible single-use biomanufacturing platform, at its headquarters in St. Louis to manufacture product candidates for Symphogen.

Source: Gallus